This trial is evaluating whether Elotuzumab will improve 2 primary outcomes and 4 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of 28 days.
This trial requires 24 total participants across 1 different treatment group
This trial involves a single treatment. Elotuzumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"A mean age of 60 years was calculated for the whole group of patients and 56 years for the male group, thus patroting a male predominance of the disease with respect to its incidence (3:1). Interestingly, patients diagnosed at an earlier age had worse survival outcomes compared with those diagnosed later." - Anonymous Online Contributor
"Elotuzumab is a humanized monoclonal antibody targeting CD22, a cell surface antigen present on B cells and T cells. It is being developed for the treatment of relapsed or refractory chronic lymphocytic leukemias and chronic lymphocytic leukemia (CLL)/small lymphocyte lymphoma (SLL). In April 2014, elotuzumab entered phase III clinical trials for relapsed chronic lymphocytic leukaemia (CLL) and relapsed follicular lymphoma (FL) patients who had received at least two prior systemic therapies. Results from these studies were published in 2015. Elotuzumab was approved by the U.S." - Anonymous Online Contributor
"The developments in MM therapy have been remarkable over the past decade. However, many of them still need further investigation. Nevertheless, advances in our knowledge of MM biology have allowed us to pursue novel therapeutic approaches. In particular, MM is now treated with drugs such as lenalidomide and thalidomide that target the immunoglobulin light chain (IgLC). These drugs induce apoptosis in MM cells and increase survival of MM patients who relapse after autologous stem cell transplantation (ASCT). Lenalidomide has also shown efficacy in newly diagnosed MM patients (before ASCT), but this has not been reported with thalidomide." - Anonymous Online Contributor
"Patients with MM are able to respond to treatment and have an improved quality of life but do not experience complete remission. In our series, long-term survival was lower than expected. Survival was better in patients with a shorter disease duration and less advanced stage at diagnosis. Further studies should evaluate whether autologous stem cell transplantation provides a more favorable outcome for these patients." - Anonymous Online Contributor
"Multiple myeloma sometimes spreads to the skin but this seems to be uncommon. Also, multiple myeloma does not usually spread to the brain. The likelihood that multiple myeloma will spread to the lungs appears low. More studies are needed to investigate whether patients with multiple myeloma should receive an MRI scan of the spine every 6 months." - Anonymous Online Contributor
"The incidence of MM in the US is low at about 1 per 100,000 person years. However, the number of new cases every year is relatively high, particularly among older persons. More than half of all cases occur in individuals 65 years of age or older." - Anonymous Online Contributor
"Findings from a recent study has shown that MM does not exhibit a familial pattern. We believe that these findings contradict previous reports demonstrating increased frequency of MM among first degree relatives of patients with MM." - Anonymous Online Contributor
"Elotuzumab has been previously studied on early B-cell lymphomas, solid tumors, and other malignancies. Recent findings expands its role into MM. It shows superiority over bortezomib in treating MM and may represent a new therapeutic option. Recent findings reported here will help to define the clinical use of elotuzumab in MM." - Anonymous Online Contributor
"Most patients with MM receive some form of therapy, including alkylating agents, proteasome inhibitors, steroids, and bortezomib. Patients who present with extramedullary disease tend to have more aggressive therapy." - Anonymous Online Contributor
"Multiple myeloma is a cancer of the bone marrow characterized by the proliferation of abnormal plasma cells. We examined the epidemiology of multiple myeloma in the United States using data from the National Cancer Institute SEER database and Medicare claims. The overall incidence of MM was 4.8 per 100,000 persons per year. Incidence increased with age; men were affected more often than women." - Anonymous Online Contributor
"Eltuzumab shows promise as an effective therapy for relapsed multiple myeloma. The efficacy of this antibody justifies the further investigation of its role in combination regimens and warrants comparison against other drugs in phase II and III studies." - Anonymous Online Contributor